Mid-Year Oncology Review 2025: History Informs the Future

What are the promises and limitations of different therapeutic modalities in solid tumors? As we approach the mid-year point, we reflect on the advancements in oncology in recent years.

Ipsos Mid Year Oncology Review 2025 - History Informs the FutureIpsos explores challenges and opportunities in the development of emerging therapeutic modalities aimed at addressing solid tumors as well as prominent topics in the field including the dominance of small molecules as a time-tested and well-established modality that nonetheless continues to lead in FDA approval numbers each year; the potential of cancer vaccines to break through to the forefront owing to the opportunities created by mRNA-based neoantigens; and the journey of cell therapies as they start to penetrate solid tumor applications. 

In this white paper, supported by Ipsos’ survey of oncologists based in the US, as well as KOL interviews, we reveal 5 key themes in oncology and how past lessons inform the innovations of today.

Sign up to access the white paper

Related news

  • [Webinar] KEYS: Battle For Attention
    Communication Events replay

    [Webinar] KEYS: Battle For Attention

    In an era dominated by ad-skipping, multi-screening, and media fragmentation, the challenge for today’s marketer is no longer just “Who am I reaching?” but “Am I reaching them at all?"
  • Where is metabolic medicine heading
    Healthcare Events replay

    Where is metabolic medicine heading – and what do you need to know?

    What happens when pipeline promise becomes market reality? During this PBSS webinar, Scott Morano and Roberto Cortese expertly guide viewers through the recent transformations in metabolic therapeutics for obesity, diabetes and MASH, and where the field is heading next.
  • KEYS: Screen time
    Media Measurement Events replay

    [WEBINAR] KEYS: Screen time

    At our first KEYS webinar of the year we’ll be looking at what’s really happening on screens these days. What’s changing? What’s enduring? And how can businesses do better when it comes to engaging with people on their screens, in real time?